Medical Advocates
Nelfinavir (Viracept)
 
Conference Citations

6th IAS Conference
5th IAS Conference
Ninth Int Congress on Drug Therapy in HIV Infection
XVII International AIDS Conference
8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference
 3rd IAS Conference
6th Int Wkshp on Clinical Pharmacology of HIV Therapy

 Archived Conference Reports
Nelfinavir Main Page Main New/Newsworthy  Home Page
Last Update:  December 08, 2014
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader .
Perinatal  data are integrated with Perinatal Conference Data in the Perinatal Data Page.   Pediatric data  are integrated with
Pediatric Conference Data in the Pediatric Data Page
6th IAS Conference on HIV and Pathogenesis
 
  • POSTER
     Protease genotypes in children and adolescents failing protease inhibitor (PI) -based antiretroviral therapy (ART)
    at the Botswana-Baylor Children’s Clinical Centre of Excellence in Gaborone, Botswana
    A. Gomila, B. Kirk, M. Tolle. et al
    Poster     Abstract
  • Transplacental passage of nevirapine, nelfinavir and lopinavir
         S. van Hoog, K. Boer, J. Nellen
    Abstract
5th IAS Conference on HIV and Pathogenesis
 
  • CONFERENCE POSTER
     Phenotypic susceptibility and drug resistance profile of HIV-1 B, C and AG clones selected with
    atazanavir, lopinavir and nelfinavir
    I. Lisovsky, J.L. Martinez Cajas, M. Oliveira, D. Moisi, et al
    PDF Poster       Abstract
Ninth International Congress on Drug Therapy in HIV Infection
 
  • Safety and efficacy of lopinavir/ritonavir compared to nelfinavir-based HAART during pregnancy
         Peña JM, González MI, Pascual-Pareja JF, et al
    Abstract
XVII International AIDS Conference
 
  • The impact of nelfinavir on cancer development among HIV-infected persons
     N. Crum-Cianflone  , K. Huppler Hullsiek, A. Ganesan , et al
     Abstract
8th Int Congress on Drug Therapy in HIV Infection
 
  • 5-year outcome in 19 HIV1-positive children treated with 2 nucleoside reverse transcriptase
    inhibitors + nelfinavir as first line protease inhibitor
    B Buchholz, S Hien, M Beicher, et al
    Abstract
  • Why do patients continue on a non-boosted PI regimen? Data from a cohort of 1012 nelfinavir
    (NFV)-treated patients
    A Antela, JM Antunez, E Ortega, et al
     Abstract
  • Influence of highly active antiretroviral therapy with nelfinavir on endothelial cell-derived microparticles
    in human immunodeficiency virus-1-infected patients
     OM Korzh, G Kotchuev, OO Pavlova , et al
     Abstract
  • Role of circulating thrombomodulin level in latent progression of atherosclerosis in human
    immunodeficiency virus-1-infected patients receiving highly active antiretroviral therapy with nelfinavir
    I Korzh, V Nemtsova, I Fedotova , et al
     Abstract
XVI International AIDS Conference
 
  • No QT prolongation four nelfinavir clinical studies
    Pun E., Petersen A., Thompson M., et al
    Abstract
  • Results of a pilot study on nelfinavir ONLINE®, TDM assay of HIV protease inhibitor nelfinavir
    Burger D., Berg T., Teulen M., et al
    Abstract
  • Satisfaction and symptom surveys reported with 625mg nelfinavir tablets among HIV-infected
    individuals previously receiving 250mg nelfinavir tablets
    Abernathy K., Hardy H., Clincea R., et al
    Abstract
  • Safety and gastrointestinal tolerability of 625mg Nelfinavir tablets among HIV-Infected individuals
    previously receiving 250mg Nelfinavir tablets
    Abernathy K., Hardy H., Clincea R., Stanic A.
     Abstract
  • The HIV protease inhibitors nelfinavir and saquinavir induce epithelial apoptosis in normal and
    malignant human colorectal mucosa and cancer cell lines
    Lenzner L., Bode H., Krämer O.H., et al 
    Abstract
  • DEXA outcomes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz or both plus dual
    nucleosides: long-term results from A5005s, a substudy of ACTG 384
    Dubé M., Komarow L., Mulligan K., et al 
    Abstract
  • Relationship between circulating thrombomodulin levels and latent progression of atherosclerosis
    in HIV-1-infected patients receiving highly active antiretroviral therapy with nelfinavir
     KorzhI., Nemtsova V., Fedotova I.
    Abstract
3rd IAS Conference on HIV and Pathogenesis
 
  • Lower scores of nelfinavir metabolite M8 were associated with virological failure at 24 weeks of
    early antiretroviral therapy in primary HIV-1 vertically infected children in the Penta 7 study
     Compagnucci A, Saïdi Y, Gibb DM, et al
     Abstract
  • NFV (625 mg new formulation) boosted with RTV once daily is not an option as compared to twice
    daily regimen.
     Landman R, Peytavin G, Descamps D, et al
         Abstract
  • Reduced rates of viral load suppression at six to 12 months by saquinavir and nelfinavir
    are not solely explained by reduced adherence to therapy.
     Moore D, Hogg R, Yip B, et al
     Abstract
  • Influence of highly active antiretroviral therapy with nelfinavir on endothelial cell-derived
    microparticles in HIV-1-infected patients
    Korzh O.
         Abstract
  • Characteristics Of HIV-1 Genotyping Test After Failure With High Strengh Scheme
    With Nelfinavir As First Protease Inhibitor
    Tupinambás U., Aleixo A., Greco D.
         Abstract
  • Effects of highly active antiretroviral therapy (HAART) regimens containing the protease
    inhibitor (PI) nelfinavir on apoptosis of peripheral blood mononuclear cells.
    Míró Ò., Villarroya J., López S., Garrabou G.,     et al
         Abstract
6th International Workshop on Clinical  Pharmacology
of HIV Therapy

Nelfinavir Main Page Main New/Newsworthy  Home Page

Nelfinavir Conference Data